Integration and acquisition costs	3 Months Ended
Mar. 31, 2014
IntegrationAndAcquisitionCosts[Abstract]
Integration and acquisition costs	5. Integration and acquisition costs For the three months to March 31, 2014 Shire recorded a net charge within integration and acquisition costs of $6.6 million. This comprised a charge of $65.8 million associated with the acquisition and integration of ViroPharma, partially offset by a net credit of $59.2 million relating to the change in fair values of contingent consideration payable in relation to prior business combinations. The net credit on changes in contingent consideration liabilities principally arises on the re-measurement of contingent consideration payable on the acquisition of FerroKin Biosciences, Inc. (“FerroKin”) ($71.9 million), following the decision to place the ongoing Phase 2 clinical trial for SHP602 on clinical hold. In the first quarter of 2013 integration and acquisition costs of $4.1 million primarily related to the acquisition of Lotus Tissue Repair Inc. and the integration of FerroKin.

Integration and acquisition costs

3 Months Ended

Mar. 31, 2014

IntegrationAndAcquisitionCosts[Abstract]

5. Integration and acquisition costs

For the three months to March 31, 2014 Shire recorded a net charge within integration and acquisition costs of $6.6 million. This comprised a charge of $65.8 million associated with the acquisition and integration of ViroPharma, partially offset by a net credit of $59.2 million relating to the change in fair values of contingent consideration payable in relation to prior business combinations.

The net credit on changes in contingent consideration liabilities principally arises on the re-measurement of contingent consideration payable on the acquisition of FerroKin Biosciences, Inc. (“FerroKin”) ($71.9 million), following the decision to place the ongoing Phase 2 clinical trial for SHP602 on clinical hold.

In the first quarter of 2013 integration and acquisition costs of $4.1 million primarily related to the acquisition of Lotus Tissue Repair Inc. and the integration of FerroKin.